EUVIMEDOpdag EUVIMED
LeitlinieOpen access · CC BY-NC 3.0

Adherence to Inhaled Medication Guidelines in Patients with COPD: Evaluating the GOLD 2023 Strategy in a Real-World Secondary Care Setting

Liz J A Cuperus, Gina De Jong iD, Erik W M A Bischoff, Job F M Van Boven iD, Job Van der Palen iD, Joachim G J V Aerts, Huib A M Kerstjens iD, Johannes C C M In't Veen iD

International Journal of Chronic Obstructive Pulmonary Disease · 2025

DOI: 10.2147/copd.s543458 ↗

At a glance

Leitlinie in International Journal of Chronic Obstructive Pulmonary Disease, 2025. Written by Liz J A Cuperus and 7 co-authors. Institution: Pulmonology Department, Franciscus Gasthuis and Vlietland, Rotterdam, the Netherlands. Major MEDLINE topics: Pulmonary Disease, Chronic Obstructive, Guideline Adherence, Practice Guidelines as Topic, Practice Patterns, Physicians'. Cited 2 times so far (Crossref); 38 references. The full text is freely available (open access, CC BY-NC 3.0). Funded by: Chiesi Pharmaceuticals B.V.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Introduction

The 2023 Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy introduced updates to the prescription of inhaled medication, including withdrawing recommendation of long-acting beta-agonist/inhaled corticosteroids (LABA/ICS) as double therapy, restricting ICS use to patients with exacerbations, and recommending earlier escalation to triple therapy. These changes are expected to have a substantial impact on clinical practice. This study aims to describe how well clinicians adhere to the GOLD strategy in daily practice, and to explore the extent to which the 2023 update has changed prescribing patterns.

Methods

Data were collected from a real-world cohort at a teaching hospital in the Netherlands in 2022, and the same cohort was reassessed in 2023. To determine guideline adherence, each patient's treatment was assessed against the applicable GOLD strategy at that time. Subgroups that did not receive treatment according to the GOLD strategy were identified. Finally, a more detailed assessment of ICS prescriptions and their indications was conducted.

Results

A total of 1318 patients were included in 2022. In 2022, 51.6% received inhaled medication in line with the applicable GOLD strategy, compared to 57.3% in 2023 in accordance with that year's GOLD strategy. Patients with low eosinophils, those without exacerbations, and those with less severe GOLD classification were less frequently treated in accordance with the 2023 strategy. Overtreatment with ICS was common (25.4%). Conclusion/Discussion: A substantial proportion of patients with COPD are not treated in accordance with GOLD recommendations. While there may be valid reasons for deviating from the recommendations, these findings should prompt physicians to consider whether their patients' current treatment is optimal. Clear criteria exist for initiating ICS treatment. However, there is no data-driven evidence or consensus on how to manage ICS treatment once a patient has stabilised. Identifying and discussing the barriers for implementation of the GOLD strategy is essential.

Subjects

MeSH terms (MEDLINE)

Pulmonary Disease, Chronic ObstructiveGuideline AdherencePractice Guidelines as TopicPractice Patterns, Physicians'Bronchodilator AgentsAdrenal Cortex HormonesSecondary Health CareAdrenergic beta-2 Receptor AgonistsLungHumansAdministration, InhalationMaleFemaleAgedMiddle AgedNetherlandsTreatment OutcomeDrug Therapy, CombinationTime FactorsHospitals, Teaching

Author keywords

COPDGOLD strategyguideline adherenceinhaled medication prescription

Substances

Bronchodilator AgentsAdrenal Cortex HormonesAdrenergic beta-2 Receptor Agonists

Authors and institutions

  • Pulmonology Department, Franciscus Gasthuis and Vlietland, Rotterdam, the Netherlands.
  • Pulmonology Department, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
  • Pulmonology Department, Erasmus University Medical Center, Rotterdam, the Netherlands.
  • Department of Business Intelligence, Franciscus Gasthuis and Vlietland, Rotterdam, the Netherlands.
  • Department of General Practice Erasmus University Medical Center, Rotterdam, the Netherlands.
  • Department of Clinical Pharmacy & Pharmacology Groningen Research Institute for Asthma and COPD (GRIAC), University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.

ORCID profiles: Gina De Jong, Job F M Van Boven, Job Van der Palen, Huib A M Kerstjens, Johannes C C M In't Veen

Funding

  • Chiesi Pharmaceuticals B.V

Cite

APA

Cuperus, L. J. A., De Jong, G., Bischoff, E. W. M. A., Van Boven, J. F. M., Van der Palen, J., Aerts, J. G. J. V., Kerstjens, H. A. M., & In't Veen, J. C. C. M. (2025). Adherence to Inhaled Medication Guidelines in Patients with COPD: Evaluating the GOLD 2023 Strategy in a Real-World Secondary Care Setting. International Journal of Chronic Obstructive Pulmonary Disease. https://doi.org/10.2147/copd.s543458

Vancouver

Cuperus LJA, De Jong G, Bischoff EWMA, Van Boven JFM, Van der Palen J, Aerts JGJV, et al. Adherence to Inhaled Medication Guidelines in Patients with COPD: Evaluating the GOLD 2023 Strategy in a Real-World Secondary Care Setting. International Journal of Chronic Obstructive Pulmonary Disease. 2025. doi:10.2147/copd.s543458

BibTeX
@article{Cuperus2025,
  author = {Cuperus, Liz J A and De Jong, Gina and Bischoff, Erik W M A and Van Boven, Job F M and Van der Palen, Job and Aerts, Joachim G J V and Kerstjens, Huib A M and In't Veen, Johannes C C M},
  title = {Adherence to Inhaled Medication Guidelines in Patients with COPD: Evaluating the GOLD 2023 Strategy in a Real-World Secondary Care Setting},
  journal = {International Journal of Chronic Obstructive Pulmonary Disease},
  year = {2025},
  doi = {10.2147/copd.s543458}
}
Start for free →